Evidence map›Paper›PMID 37751987›Full record

ArticleBMJ case reports2023

Clinical effects of tranexamic acid on bleeding tendency due to fibrinolytic activation of AL amyloidosis.

Gaku Matsumoto, Hideki Mori, Takahiro Mori, Chika Sakaki

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Gaku MatsumotoDepartment of General Internal Medicine, National Hospital Organisation Nagasaki Medical Center, Omura, Nagasaki, Japan.ORCID http://orcid.org/0000-0002-6183-5672
Hideki MoriDepartment of General Internal Medicine, National Hospital Organisation Nagasaki Medical Center, Omura, Nagasaki, Japan mori.hideki.fu@mail.hosp.go.jp.ORCID http://orcid.org/0000-0002-5778-4833
Takahiro MoriDepartment of General Internal Medicine, National Hospital Organisation Nagasaki Medical Center, Omura, Nagasaki, Japan.
Chika SakakiDepartment of Hematology, National Hospital Organisation Nagasaki Medical Center, Omura, Nagasaki, Japan.
Nagasaki Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case where tranexamic acid, which is an antifibrinolytic agent, was used to effectively treat bleeding tendency in a patient with immunoglobulin light chain (AL) amyloidosis. A male patient in his 80s without a history of bleeding disorders was admitted to our hospital for the examination of bleeding tendency and was diagnosed with a bleeding disorder due to AL amyloidosis. Blood tests revealed elevated plasmin-α2-plasmin inhibitor complex levels, suggesting fibrinolytic activation. Managing the bleeding was difficult; however, we suspected fibrinolytic activation associated with AL amyloidosis and initiated treatment with oral tranexamic acid, which markedly improved the bleeding disorder and abnormalities of the fibrinolytic system. Therefore, in cases of bleeding due to fibrinolytic activation of AL amyloidosis, tranexamic acid administration can be an effective treatment.

Indexed as

Antifibrinolytic AgentsHemorrhageImmunoglobulin Light-chain AmyloidosisTranexamic AcidAged, 80 and overFibrinolysisHumansMaleTreatment OutcomeAntifibrinolytic AgentsTranexamic AcidHaematology (incl blood transfusion)Monoclonal gammopathy of undetermined significance associated neuropathyPalliative care

Identifiers

PMID37751987
PMCPMC10533652
OpenAlexW4387063660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.